0.3700 -0.17 (-31.48%)
Before hours: 8:38AM EDT
|Bid||0.3760 x 3200|
|Ask||0.3798 x 1100|
|Day's Range||0.4701 - 0.7897|
|52 Week Range||0.4000 - 2.9600|
|Beta (5Y Monthly)||2.67|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Aeterna Zentaris Inc. (AEZS) (AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced the pricing of a public offering of 26,666,666 units at a price to the public of $0.45 per unit, for gross proceeds of $12 million, before deducting placement agent fees and other offering expenses payable by the Company. Each unit contains one common share (or common share equivalent) and one common warrant to purchase one common share. The common shares (or common share equivalents) and common share warrants included in the units can only be purchased together in this offering but will be issued separately and will be immediately separable upon issuance.
Aeterna Zentaris Inc. (AEZS) (AEZS.TO) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has entered into an exclusive distribution and related quality agreement (the “Agreement”) with Megapharm Ltd. (“Megapharm”), a leading Israel-based biopharmaceutical company, for the commercialization in Israel and the Palestinian Authority of macimorelin, Aeterna Zentaris’ orally available ghrelin agonist to be used in the diagnosis of patients with adult growth hormone deficiency (“AGHD”) and child-onset growth hormone deficiency (“CGHD”). Under the terms of the agreement, Megapharm will be responsible for obtaining registration to market macimorelin in Israel and the Palestinian Authority, while Aeterna Zentaris will be responsible for manufacturing, product supply, quality assurance and control, regulatory support, and maintenance of IP.
Aeterna Zentaris Inc. (AEZS) (AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that it has regained compliance with the minimum bid price for continued listing on the Nasdaq Capital Market, as the closing bid price of the Company’s common stock has been at $1.00 or greater for 10 consecutive trading days. On April 8, 2020, the Company received notice that its common stock failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days as required by Nasdaq. Now that the Company has regained compliance with this listing rule, Nasdaq has advised the Company that this matter is now closed.
Aeterna Zentaris Inc. (AEZS) (AEZS) ( the “Company”), a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests, today announced that the Company has received a positive decision from the staff of the Listing Qualifications Department of The Nasdaq Stock Market LLC (the “Staff”), granting the Company’s request for an extension through October 5, 2020 to achieve compliance with the minimum $2.5 million stockholders‘ equity requirement for continued listing on The Nasdaq Capital Market. The Staff’s determination followed the Company’s submission of its compliance plan for the Staff’s consideration on May 26, 2020. The Company is pursuing a number of initiatives to increase stockholders‘ equity, the completion of which are expected to enable it to achieve compliance with the minimum stockholders’ equity requirement by no later than October 5, 2020 and to thereafter maintain compliance with the listing requirements.
The individuals noted below were elected as Directors of the Company. The Company would like to welcome Peter Edwards to the Board of Directors. The Company would also like to extend its sincere thanks and best wishes to Gérard Limoges, Dr. Brent Norton, and Robin Smith Hoke who have been valued members of Aeterna’s Board of Directors.
Shareholders will not be able to attend the AGM in-person at a physical location. To be admitted to the virtual AGM, shareholders need to visit www.virtualshareholdermeeting.com/AEZS2020 and enter the control number included on the proxy form or voting instruction form, as applicable. Aeterna Zentaris strongly encourages its shareholders to read its management proxy circular dated April 2, 2020 and other AGM materials carefully.
The Company also provided an update on its clinical program to develop macimorelin for the diagnosis of child-onset growth hormone deficiency (“CGHD”), an area of significant unmet need, and its plans to expand macimorelin for the diagnosis of adult growth hormone deficiency (“AGHD”) in Europe. With these positive Study P01 results, we have the necessary data to lay the foundation for our test validation, Study P02, which we expect to commence later this year.
Gilead Sciences’ antiviral drug remdesivir showed “quite good news,” according to White House health advisor Dr. Anthony Fauci. Assistant Professor in Department of Health Policy and Management at the Harvard Global Health Institute Dr. Tom Tsai joins Yahoo Finance’s Seana Smith to discuss the latest developments.
CHARLESTON, S.C., April 15, 2020 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna Zentaris” or the “Company”), a specialty biopharmaceutical company.
A live audio webcast of the presentation will be available on the Events and Presentations page of the Investors section of the Company’s website (www.zentaris.com). The Company’s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD).
– Modifications recommended for some key elements of planned safety and efficacy Study P02 – – Modifications to the outline of Study P02 requested to ensure a harmonized global.
This study, AEZS-130-P01 (“Study P01”), was the first of two studies as agreed with the European Medicines Agency (“EMA”) in the Company’s Pediatric Investigation Plan (“PIP”) for macimorelin. The goal of Study P01 was to establish a dose that could both be safely administered to pediatric patients and cause a clear rise in growth hormone concentration in subjects ultimately diagnosed as not having GHD.
Timothy C. Wentworth, Express Scripts Holding Company and Cigna Services President, joins Yahoo Finance’s Alexis Christoforous and Brian Sozzi to discuss how health insurance companies are faring amid the coronavirus outbreak.
– Strengthened cash position with recently closed financing as well as royalty payments from Novo Nordisk for U.S. sales of Macrilen™ – – Robust ongoing business development.
The settlement payment will be funded entirely by the Company’s insurers. The previously disclosed class-action lawsuit alleged that the Company and certain of its current and former officers and directors violated the Securities Exchange Act of 1934 in connection with certain public statements made between August 30, 2011 and November 6, 2014, regarding the safety and efficacy of Macrilen™ (macimorelin) and the prospects for the approval of the Company's New Drug Application for the product by the FDA.
Additionally, the Company issued to the investors unregistered warrants to purchase up to an aggregate of 2,608,696 common shares in a concurrent private placement. The warrants have an exercise price of $1.20 per common share, are exercisable immediately and will expire five and one-half years following the date of issuance. The gross proceeds to the Company from the offering totaled approximately $4.5 million, before deducting placement agent fees and offering expenses.
The offering is expected to result in gross proceeds to Aeterna Zentaris of approximately $4.5 million. Aeterna Zentaris will also issue to the purchasers unregistered warrants to purchase up to an aggregate of 2,608,696 common shares. The warrants will be exercisable for a period of five and one-half years, exercisable immediately following the issuance date and have an exercise price of $1.20 per common share.
As part of his presentation, Dr. Paulini will provide a corporate overview and update on the Company’s lead product, Macrilen™ (macimorelin), the only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Dr. Paulini’s slide presentation will be made available on the Company’s website on Monday, February 17th.
– Study P01 is the first of two studies as agreed with the EMA in the Company’s Pediatric Investigation Plan for macimorelin as a growth hormone deficiency diagnostic – – Study.
CHARLESTON, S.C., Jan. 27, 2020 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company engaged in.
Aeterna Zentaris Inc. (AEZS) (AEZS) today announced that it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") indicating that, because the closing bid price of the Company’s common stock for 30 consecutive business days was below $1.00 per share, the Company no longer meets the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2). Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days.
CHARLESTON, S.C., Dec. 18, 2019 -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) is pleased to announce that the American Association of Clinical Endocrinologists (AACE) and.
Aeterna Zentaris Inc. (AEZS) (AEZS) is pleased to announce changes to its director composition planned for the first quarter of 2020. Mr. Gilles Gagnon (M.Sc., MBA, ICD.D) will join the board of directors of the Company on January 1, 2020. Mr. Gérard Limoges, who has served on the board of directors of the Company since 2004, is planning to retire from the board of directors on March 31, 2020, and upon his retirement Mr. Pierre-Yves Desbiens (CPA, CA, CF, MBA) will join the board and replace Mr. Limoges as Chair of the Audit Committee.